BioCentury This Week

BioCentury This Week

Download on the App Store

BioCentury This Week episodes

  • Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds

    J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the terms of the deal, what it says about NewCos as an exit path and Blackstone Life Sciences’ role in funding Phase III.
    The analysts also assess how a growing neoantigen vaccine pipeline is testing the modality’s reach after Merck and Moderna’s Phase III win in melanoma, and the White House push that has put Heidi Overton back in play ahead of the Nov. 18 Senate HELP Committee vote on her nomination as FDA commissioner. This episode of the BioCentury This Week podcast has been brought to you by Tigermed.

    View full story: https://www.biocentury.com/article/661638

     #NewCos #BiotechMA #CancerVaccines #FDA #Ophthalmology 

    0:01 Sponsor Message: Tigermed
    1:58 J&J’s Ollin Acquisition
    5:18 Blackstone’s Risk Sharing
    9:13 Neoantigen Vaccine Pipeline
    17:29 Overton’s FDA Nomination
    24:40 Acting Commissioner Scenarios

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    29 min
  • Ep. 397 - What the U.S. midterms mean for biopharma

    Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipartisan drug pricing legislation. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation.
    The analysts also unpack full Phase III data showing pelacarsen failed across all subgroups and what it means for Lp(a) as a cardio target, highlight SITC abstracts on localizing immunotherapy within solid tumors, and discuss argenx’s $550 million upfront buyout of Unnatural Products. This episode of the BioCentury This Week podcast has been brought to you by Tigermed.

    View full story: https://www.biocentury.com/article/661519

    #BiotechPolicy #FDA #DrugPricing #Cardiovascular #Immunotherapy

    0:01 Sponsor Message: Tigermed
    5:06 FDA Leadership After Midterms
    12:41 HHS and Drug Pricing
    17:34 Pelacarsen Readout at AHA
    22:31 SITC Abstract Highlights
    25:57 argenx’s Peptide Deal

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    29 min
  • Ep. 396 - China’s first-order innovation

    Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th BioCentury-BayHelix China Healthcare Summit in Shanghai, BioCentury’s Jeff Cranmer, Simone Fishburn and Josh Berlin are joined by Kali Therapeutics CEO Weihao Xu, Charles River’s Matthew Hewitt and Aerska CEO Jack O’Meara to discuss key themes from the event.
    The panel assesses what the COINS Act could mean for U.S. investment in China biotech and how investors may adapt, how China’s 30-day IND review and new investigator-initiated trial rules are reshaping clinical strategy, and what dealmaking reveals about the country’s growing first-in-class pipeline. They also preview BioCentury’s East-West Summit in Seoul, March 15-17.

    View full story: https://www.biocentury.com/article/661483

    #ChinaBiotech #COINSAct #ClinicalTrials #FirstInClass #BiotechPartnering

    0:00 Live from China Healthcare Summit
    5:20 China's Role in Biotech R&D
    9:06 What COINS Could Mean for U.S. Investors
    11:37 Faster IND Reviews and New IIT Rules
    17:27 First-Order Innovation in China

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    30 min
  • Ep. 395 - ESMO analysis & Auchincloss proposal

    A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discuss why new targets alone may not be enough to overcome resistance.
    Turning to policy, the analysts examine Representative Jake Auchincloss’ Faster Clinical Trials Act, which would embed trials in routine care and expand the NIH's All of Us biobank. They also discuss how U.S. investors are reacting to Treasury's proposed COINS Act rule, including a workaround that pays Chinese licensors on exit instead of with equity, and former FDA Commissioner Janet Woodcock's proposals to make individualized rare disease therapies commercially viable.

    View full story: https://www.biocentury.com/article/661405

    #ADCs #ClinicalTrials #BiotechPolicy #ChinaBiotech #RareDisease

    0:00 Introduction
    1:34 ESMO First-in-Human Analysis
    10:26 Faster Clinical Trials Act
    19:27 COINS Act and NewCos
    28:19 Woodcock's Rare Disease Proposals
    31:53 Biotech IPO Debuts

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    34 min
  • Ep. 394 - Security concerns in U.S., China reshaping biotech

    Proposed U.S. Treasury rules implementing the COINS Act would bar U.S. equity investments, joint ventures and co-development deals with China biotechs, potentially ensnaring Asia-to-West NewCos while leaving licensing intact. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the rule’s implications for cross-border dealmaking, the competitive opening it may create for European companies, and China’s narrower-than-feared draft export controls on platform technologies.
    The analysts also discuss what drew Gilead to pay $1.3 billion up front for stealth Shanghai biotech PepStar’s oral IL-23 peptide, and whether Merck and Moderna’s Phase III melanoma vaccine data clear the bar for adoption.

    View full story: https://www.biocentury.com/article/661319

    #BiotechPolicy #ChinaBiotech #CrossBorderDeals #NewCos #CancerVaccines

    00:00 Introduction
    01:31 Treasury's COINS Act Proposal
    05:15 NewCos Under COINS
    13:20 China's Draft Export Controls
    18:39 Pepstar's Gilead Deal
    23:24 Merck-Moderna Melanoma Vaccine

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    34 min
  • Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau

    Roche’s $15 billion biobucks deal with Hansoh for preclinical ADCs is the latest in a string of China licensing deals carrying unusually large upfronts for early-stage assets. On the latest BioCentury This Week podcast, BioCentury’s analysts assess trends to watch ahead of Shanghai Life Sciences Week, including how new rules have curtailed China’s IIT pathway and a proposed export-control regime that could complicate cell and gene therapy and siRNA deals.
    The analysts also discuss Merck KGaA’s $1.3 billion takeout of Silence, Arrowhead’s brain-shuttle tau data and the dose dilemma facing tau-lowering therapies, and whether a preclinical biotech like Isomorphic Labs can justify a $40-50 billion valuation.

    View full story: https://www.biocentury.com/article/661224

    #ChinaBiotech #siRNA #BiotechMA #DrugDiscovery #DrugDevelopment

    0:00 Introduction
    1:13 China Trends
    9:00 Roche-Hansoh Deal
    13:11 Merck KGaA Buys Silence
    15:38 Arrowhead's Brain Shuttle
    23:40 Isomorphic Labs Valuation

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    31 min
  • Ep. 392 - Biotech markets: Pause before the storm?

    An M&A-fueled first half gave way to third-quarter underperformance for biotech as a short squeeze in Moderna forced specialist funds into selling some quality names and follow-on activity slowed. On the latest BioCentury This Week podcast, BioCentury’s analysts preview the fourth quarter, where rising bond yields and the U.S. midterms could keep financing and deal activity quiet through year-end.
    The analysts also discuss why late-stage misses in Lp(a), IL-6, and Factor XI are pushing developers to rethink secondary prevention trial design, and PhRMA’s lawsuit to block CMS’s Globe Part B model, which could determine whether future administrations can impose international reference pricing without Congress.

    View full story: https://www.biocentury.com/article/661134

    #BiotechMarkets #DrugPricing #CardiovascularDisease #ClinicalTrials #FDA
     
    0:00 Introduction
    1:10 Biotech Market Outlook
    11:40 CV Trial Design Rethink
    18:24 PhRMA vs. GLOBE

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    25 min
  • Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

    Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington.
    The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the precedent it sets than for its savings, and the Nobel Prize for optogenetics as the first therapy based on the technology nears an FDA decision.

    View full story: https://www.biocentury.com/article/661028

    #ChinaBiotech #DrugPricing #IntellectualProperty #DrugDevelopment #NobelPrize

    0:00 Introduction
    1:30 China Pharma Deal Trends
    11:29 Beam vs. YolTech Lawsuit
    20:01 Small GLOBE, Big Precedent
    24:05 Nobel Prize & Optogenetics

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    31 min
  • Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

    Mechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging, emerged as a defining theme at Grand Rounds Europe in Amsterdam. On a special live edition of the BioCentury This Week podcast, BioGeneration Ventures' Oskar Slotboom, NautaDutilh's Ruud Smits and Leyden Labs' Dinko Valerio join BioCentury's analysts to discuss women's health and sleep as lenses on disease, and the shift toward prevention.
    The panel also weighs the limits of "Frankenstein" multiparatopic molecules and AI-driven discovery, knowledge gaps in autonomous labs, new China first-in-human rules, and what Novartis' Lp(a) miss means for genetically validated targets.

    View full story: https://www.biocentury.com/article/660970

    #EuropeBiotech #DrugDiscovery #TranslationalMedicine #GeneticTargets #HealthSpan

    0:00 Introduction
    2:10 Bridging Academia & Industry
    14:51 Key Themes
    26:02 Toolbox and Biology
    31:05 Lp(a) Fallout & Genetic Targets

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    35 min
  • Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

    Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals.
    The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and lingering questions about her independence, new pharma tariff guidance that leaves exemptions unclear, and how reverse mergers paired with nine-figure PIPEs became a viable IPO alternative. Plus, Merck's $400 million upfront bet on a preclinical KRAS G12C molecular glue.

    View full story: https://www.biocentury.com/article/660935

    #IgANephropathy #FDA #BiotechIPO #DrugDevelopment #ClinicalTrials

    0:00 Introduction
    1:30 Grand Rounds: Europe Recap
    6:03 IgA Nephropathy Pipeline
    14:57 Overton Hearing
    22:19 Commerce's Tariff Guidance
    24:28 Reverse Mergers' New Look

    To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

    Reach us by sending a text

    38 min

About BioCentury This Week

From the publisher's feed

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical…

More shows like BioCentury This Week

Freakonomics Radio by Freakonomics Radio + Stitcher

Freakonomics Radio

31,952 Listeners

Bloomberg Intelligence by Bloomberg

Bloomberg Intelligence

407 Listeners

Odd Lots by Bloomberg

Odd Lots

2,125 Listeners

Nature Podcast by Springer Nature Limited

Nature Podcast

770 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

124 Listeners

The Readout Loud by STAT

The Readout Loud

338 Listeners

Making Sense by J.P. Morgan

Making Sense

66 Listeners

Thoughts on the Market by Morgan Stanley

Thoughts on the Market

1,297 Listeners

Biotech 2050 Podcast by Biotech 2050

Biotech 2050 Podcast

62 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

86 Listeners

MIT Technology Review Narrated by MIT Technology Review

MIT Technology Review Narrated

261 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Biotech Hangout

20 Listeners

WSJ's Take On the Week by The Wall Street Journal

WSJ's Take On the Week

145 Listeners

The Top Line by Fierce Life Sciences

The Top Line

14 Listeners

The BioCentury Show by BioCentury

The BioCentury Show

11 Listeners